Lonza, a global leader in the field of viral manufacturing and cell processing, has completed the validation of its new viral-induced cell processing GMP suites in Houston, Texas and have also completed the tech transfer process for a new virally-transfected T-cell product.
“We are pleased to have been selected by our existing viral vector client to additionally perform the development and manufacture of virally-modified cellular products to support its clinical studies. Lonza is a leader in the contract manufacture of protein, cell, and virus-based products. As the field of regenerative medicine expands to include combination products, we are pleased to grow with the field and offer seamless contract manufacturing services for the development and manufacture of these unique products, said David Enloe, Head of Viral-based Therapeutics, Lonza.
Last summer, Lonza announced the expansion of its GMP facilities in Houston in order to better serve the needs of customers (Lonza Houston facility expansion). With the addition of these cell processing suites, Lonza can accept clients developing virally-modified autologous cellular immunotherapies, a rapidly growing segment in the regenerative medicine space.
Lonza offers a full range of services that cell and gene therapy clients rely upon for commercial success. Each client is provided with a team of scientists equipped with the knowledge and experience required to translate therapies into scalable, clinical-grade products complete with process development activities, product quality testing, product storage, and distribution.
EP News Bureau